No adverse effects were reported in the trial.
The WOMAC scores demonstrate significant
improvement in pain, stiffness and physical disability
for patients with knee osteoarthritis. The scores were
reduced significantly in all the parameters under
consideration hence substantiating the efficacy of
NILIN SR. Similarly on application of the visual
analogue scale pain score, very dramatic improvement
is seen over the course of 4 hours after ingestion of
the tablet from Day 6 onwards, for the rest of the trial.
The immediate onset pain relief which progressively
improves in the trial is apparent. The mean distance
covered in 6 minutes too increased noticeably and was
consistently more than that seen at the baseline.
Furthermore, no adverse effects were noted in the
trial. A multitude of disadvantages are incurred with
the standard line of treatment so far followed by
clinicians worldwide for osteoarthritis, and hence
safer and naturally active agents are a crying need of
the hour. This clinical study brings forth NILIN SR as
a new line of treatment, which is both safe and
effective, for patients of Osteoarthritis. Further
evaluation in larger study samples will affirm its
utility in the management of osteoarthritis.